-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ranibizumab Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ranibizumab Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ranibizumab Biosimilar in Wet (Neovascular /...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XEN-1101 in Partial Seizure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XEN-1101 in Partial Seizure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XEN-1101 in Partial Seizure Drug Details: XEN-1101 (1OP-2198) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avelumab in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avelumab in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Avelumab in Small-Cell Lung Cancer Drug Details: Avelumab (MSB-0010718C, Bavencio)...
-
Product Insights
Cartilage Degeneration – Drugs In Development, 2023
Global Markets Direct’s, ‘Cartilage Degeneration - Drugs In Development, 2023’, provides an overview of the Cartilage Degeneration pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cartilage Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Endocrine Gland Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Endocrine Gland Disorders - Drugs In Development, 2023’, provides an overview of the Endocrine Gland Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Endocrine Gland Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...